Putting together a summary on the scale has not moved in since I keep seeing the same questions pop up.
I am not a medical professional (just a well-researched patient) so take this with appropriate salt, but I have compiled info from the clinical trials.
Happy to be corrected by the actual clinicians here — that is the whole point of posting it.
JenPlateau said:The scale has not moved in 3 weeks - I am losing my mind
Gonna push back on this one. The scale has not moved in 3 weeks is not that straightforward in my experience. I have been on this for 12 months and the reality is messier than the trials suggest.
Don't get me wrong — the medication works. But cost accessibility is a real barrier. We should be honest about that.
JenPlateau said:The scale has not moved in 3 weeks - I am losing my mind
This is exactly right. JenPlateau articulated what I have been trying to explain to my doctor for months. The The scale has not moved aspect is the most important factor.
Clinical perspective on The scale has not moved in 3 weeks - I:
I have managed ~150 patients on GLP-1 therapy and this topic comes up frequently. What the data shows — and what I see in practice — is that proper titration prevents most adverse events.
For this specific question, I would recommend: reviewing the relevant clinical guidelines.
LibrarianMeg said:JenPlateau articulated what I have been trying to explain to my doctor for months
I respect LibrarianMeg perspective but I think this oversimplifies things a bit. Re: The scale has not moved in 3 — the effect size varies considerably by population.
I am not saying LibrarianMeg wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.